$17.030
0.000 (0.00%)收盤時
TBPH 資訊
TBPH 事件
Zymeworks Completes Acquisition of Theravance Biopharma
LifeSci Capital notes Zymeworks (ZYME) announced the completion of the Theravance Biopharma (TBPH) acquisition. Yupelri is expected to be immediately accretive to revenue and cash flow, with a mid-teens IRR as the base case. Zymeworks emphasized commercial expansion opportunities in both community and hospital settings, noting that Yupelri remains under-penetrated, with a "single-digit" penetration rate in a large COPD market of 15M-16M patients, of whom about 2M are "well-suited" for a nebulized product, the firm notes. The company will retain Theravance's "small, high-performing" commercial team, although details on the sales force were not provided. Management intentionally remained conservative on providing detailed financial guidance, while underscoring that the company remains focused on cost discipline with respect to operating expenses. LifeSci has an Outperform rating on Zymeworks with a price target of $34.
Theravance Biopharma to be Acquired by Zymeworks
"During the second quarter, we entered into a definitive agreement to be acquired by Zymeworks, marking the culmination of a comprehensive strategic review process and what we believe achieves the greatest value for Theravance Biopharma shareholders," said Rick Winningham, Chief Executive Officer of Theravance Biopharma. "At the same time, YUPELRI delivered another strong quarter, underscoring the durability and value of our core commercial asset and the continued execution of our collaboration with Viatris. We continued to execute well against our restructuring plan and expect to close the Zymeworks transaction in the second half of 2026 subject to shareholder approval and customary closing conditions."
H.C. Wainwright Downgrades Theravance Biopharma to Neutral with $17 Price Target
H.C. Wainwright downgraded Theravance Biopharma (TBPH) to Neutral from Buy with a $17 price target after the company announced an agreement to be acquired by Zymeworks (ZYME) for $17 per share in cash.
BTIG Downgrades Theravance Biopharma to Neutral
BTIG downgraded Theravance Biopharma (TBPH) to Neutral from Buy after Zymeworks (ZYME) announced it has agreed to acquire the company for $17 per share. The firm does not anticipate any materially higher offers and expects the deal to close in the second half, the analyst tells investors.
Nasdaq Futures Rise, PetMed Express Stock Soars 32%
Stock futures are higher before the open, with the Nasdaq leading gains as investors move back toward growth and technology names after last week's pressure. Oil prices are also easing from recent highs, reducing fears that a geopolitical shock could spill into inflation expectations.The key theme this week is shifting from geopolitics back toward macro data. Investors are watching labor market releases, including JOLTS and Thursday's payroll report, for clues on the Federal Reserve path. Markets continue to weigh a resilient economy against concerns that sticky inflation could keep the Fed more restrictive than expected.In pre-market trading, S&P 500 futures rose 0.76%, Nasdaq futures rose 1.03% and Dow futures rose 0.41%.Check out this morning's top movers from around Wall Street, compiled by The Fly.HIGHER -PetMed Expressup 32% after SilverCape Investments released an open letter to its board of directors calling on the board to engage with SilverCape on a revised proposal to acquire all outstanding shares of common stock of PetMed for $3.00 per share in cash with no financing contingencyCharterand SpaceXand up 24% and 2%, respectively, after a report that the companies discussed partnering on a consumer mobile phone offeringComcastup 21% after announcing its intention to separate into two independent publicly traded companies through a tax-free spin-off of NBCUniversal and SkyIridiumand Rocket Labup 22% and 9%, respectively, after Rocket Lab agreed to acquire all the outstanding shares of Iridium common stock for $54 per share in a cash and stock transactionLOWER -Zymeworksand Theravance Biopharmaboth down 2% after Zymeworks entered into a definitive agreement to acquire Theravance Biopharma for $17.00 per shareMartin Mariettadown 2% after entering into a definitive agreement to combine with Lhoist North America, a subsidiary of Lhoist Group, for $13.5B in cash and shares of Martin Marietta common stockBritish American Tobaccodown 1% after reporting its Fit2Win cost-cutting initiatives will impact 9,000 jobsVerizondown 1% after BT Groupand the company announced the signing of an agreement to combine their respective international enterprise operations into a 50:50 joint venture
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。